<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl" ?><document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="edc24a6c-4754-4695-af73-de2797457ba7"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Donnatal Tablets</title>
   <effectiveTime value="20131203"/>
   <setId root="7343cfab-9bd9-4dcb-bbef-9592ffd5d7e6"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="079239644" root="1.3.6.1.4.1.519.1"/>
            <name>Carilion Materials Management</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="079239644" root="1.3.6.1.4.1.519.1"/>
                  <name>Carilion Materials Management</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="079239644" root="1.3.6.1.4.1.519.1"/>
                        <name>Carilion Materials Management</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68151-0607" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="c6627264-050b-490e-bdc0-ff470ce3418f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <title/>
               <text/>
               <effectiveTime value="20131203"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68151-0607" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Donnatal</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="66213-425" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="16.2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YQE403BP4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENOBARBITAL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YQE403BP4D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENOBARBITAL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.1037"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F2R8V82B84" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYOSCYAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="PX44XO846X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYOSCYAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.0194"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="03J5ZE7KA5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATROPINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7C0697DR9I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATROPINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.0065"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451IFR0GXB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SCOPOLAMINE HYDROBROMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="DL48G20X8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SCOPOLAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="776XM7047L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68151-0607-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20080507"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <code code="C73627" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="unapproved drug other"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48349" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SEMI-CIRCLE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;Donnatal</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L4a0adaea-e477-4640-9483-203d60a8b186">
               <id root="3ebf3454-42e8-410a-a870-48284ad122e4"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>Description</title>
               <text>
                  <paragraph>Each Donnatal® Tablet contains:</paragraph>
                  <paragraph>Phenobarbital, USP....................................... 16.2 mg</paragraph>
                  <paragraph>Hyoscyamine Sulfate, USP...................... 0.1037 mg</paragraph>
                  <paragraph>Atropine Sulfate, USP ...............................0.0194 mg</paragraph>
                  <paragraph>Scopolamine Hydrobromide, USP ...........0.0065 mg</paragraph>
                  <paragraph/>
                  <paragraph>INACTIVE INGREDIENTS: Anhydrous Lactose, Calcium Stearate, Colloidal</paragraph>
                  <paragraph>Silicon Dioxide, Corn Starch, and Microcrystalline Cellulose.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="L0c3c43ab-e2d8-4053-84af-b779a0895be5">
               <id root="1a817b6b-d80f-4ae2-9f55-0b712abaacef"/>
               <code code="51727-6" codeSystem="2.16.840.1.113883.6.1" displayName="INACTIVE INGREDIENT SECTION"/>
               <title>INACTIVE INGREDIENTS</title>
               <text>
                  <paragraph>Anhydrous Lactose, Calcium Stearate, Colloidal Silicon Dioxide, Corn Starch, and Microcrystalline Cellulose</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="L195f1311-e415-4268-8ff5-1a23898893f5">
               <id root="eca03638-8a8a-44f0-b0b3-669d3d186d92"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to</paragraph>
                  <paragraph>provide peripheral anticholinergic/antispasmodic action and mild sedation.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="L51b0fcad-c354-4bf2-a067-d51b4c94557f">
               <id root="8f6a1206-2a9f-48d0-ae0c-5dc0684e4dd7"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other</paragraph>
                  <paragraph>information, FDA has classified the following indications as “possibly” effective:</paragraph>
                  <paragraph>For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis)</paragraph>
                  <paragraph>and acute enterocolitis.</paragraph>
                  <paragraph>May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN</paragraph>
                  <paragraph>CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A</paragraph>
                  <paragraph>DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="L8a7f3331-6e9c-45ff-8325-716037c12cd5">
               <id root="bd98c2ed-e297-4b0c-874c-2a6b504de7fa"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive</paragraph>
                  <paragraph>disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of</paragraph>
                  <paragraph>the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis</paragraph>
                  <paragraph>especially if complicated by toxic mega-colon; myasthenia gravis; hiatal hernia associated with reflux esophagitis.</paragraph>
                  <paragraph>Donnatal® is contraindicated in patients with known hypersensitivity to any of the ingredients. Phenobarbital is</paragraph>
                  <paragraph>contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness</paragraph>
                  <paragraph>and/or excitement.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="La3c8dbb8-750f-4f63-9dd0-2e0e04567e2b">
               <id root="1080279f-da3b-4cc0-8b87-f543ef35bb5a"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>In the presence of a high environmental temperature, heat prostration can occur with belladonna alkaloids (fever and</paragraph>
                  <paragraph>heatstroke due to decreased sweating).</paragraph>
                  <paragraph>Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or</paragraph>
                  <paragraph>colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful.</paragraph>
                  <paragraph>Donnatal® may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to</paragraph>
                  <paragraph>engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to</paragraph>
                  <paragraph>perform hazardous work.</paragraph>
                  <paragraph>Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal</paragraph>
                  <paragraph>effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.</paragraph>
                  <paragraph>Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to</paragraph>
                  <paragraph>those with a history of physical and/or psychological dependence upon drugs.</paragraph>
                  <paragraph>Since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in</paragraph>
                  <paragraph>patients with hepatic dysfunction.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="Lb017a1b5-cfd4-415b-bf76-fc6e14b6b768">
               <id root="7b441b7d-6eaa-4db6-b079-0f4022e6d222"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph>Use with caution in patients with: autonomic neuropathy, hepatic or renal disease, hyperthyroidism, coronary heart</paragraph>
                  <paragraph>disease, congestive heart failure, cardiac arrhythmias, tachycardia, and hypertension.</paragraph>
                  <paragraph>Belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management</paragraph>
                  <paragraph>of gastric ulcer.</paragraph>
                  <paragraph>Do not rely on the use of the drug in the presence of complication of biliary tract disease.</paragraph>
                  <paragraph>Theoretically, with overdosage, a curare-like action may occur.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="Lfb30b094-bdd3-4cf5-85d1-72d3753f70a3">
               <id root="76c76ac0-8904-4cb5-98b0-9d79628e4884"/>
               <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
               <title>CARCINOGENESIS, MUTAGENESIS,
  IMPAIRMENT OF FERTILITY</title>
               <text>
                  <paragraph>Long-term studies in animals have not been performed to evaluate carcinogenic potential.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="La61c4d9b-da3e-45e0-93bd-0e51dd196dfd">
               <id root="a4fdea7b-0db8-425b-8b77-fc36bc20781b"/>
               <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
               <title>PREGNANCY</title>
               <text>
                  <paragraph>PREGNANCY CATEGORY C</paragraph>
                  <paragraph>Animal reproduction studies have not been conducted with Donnatal®. It is not known whether Donnatal® can cause</paragraph>
                  <paragraph>fetal harm when administered to a pregnant woman or can affect reproduction capacity. Donnatal® should be given to</paragraph>
                  <paragraph>a pregnant woman only if clearly needed.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="L2144e663-72d3-4472-ad9a-efdf69780dc8">
               <id root="d30a8c7c-a4c7-4a34-bdd9-8067f958b12f"/>
               <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
               <title>NURSING MOTHERS</title>
               <text>
                  <paragraph>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution</paragraph>
                  <paragraph>should be exercised when Donnatal® is administered to a nursing woman.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="L808816e8-3cb8-4595-a0ee-500b4fb25440">
               <id root="5cff4b5b-757e-4c33-b108-ea5df9add11c"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Adverse reactions may include xerostomia; urinary hesitancy and retention; blurred vision; tachycardia; palpitation;</paragraph>
                  <paragraph>mydriasis; cycloplegia; increased ocular tension; loss of taste sense; headache; nervousness; drowsiness; weakness;</paragraph>
                  <paragraph>dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling;</paragraph>
                  <paragraph>musculoskeletal pain; severe allergic reaction or drug idiosyncrasies, including anaphylaxis, urticaria and other dermal</paragraph>
                  <paragraph>manifestations; and decreased sweating. Acquired hypersensitivity to barbituates consists chiefly in allergic reactions</paragraph>
                  <paragraph>that occur especially in persons who tend to have asthma, urticaria, angiodema and similar conditions. Hypersensitivity</paragraph>
                  <paragraph>reactions in this category include localized swelling, particularly of the eyelids, cheeks, or lips, and erythematous</paragraph>
                  <paragraph>dermatitis. Rarely, exfoliative dermatitis (e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis) may be</paragraph>
                  <paragraph>caused by phenobarbital and can prove fatal. The skin eruption may be associated with fever, delirium, and marked</paragraph>
                  <paragraph>degenerative changes in the liver and other parenchymatous organs. In a few cases, megaloblastic anemia has been</paragraph>
                  <paragraph>associated with the chronic use of phenobarbital. Elderly patients may react with symptoms of excitement, agitation,</paragraph>
                  <paragraph>drowsiness, and other untoward manifestations to even small doses of the drug. Phenobarbital may produce</paragraph>
                  <paragraph>excitement in some patients, rather than a sedative effect. In patients habituated to barbiturates, abrupt withdrawal</paragraph>
                  <paragraph>may produce delirium or convulsions.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="L164d60fe-4ab0-4e8f-ad53-e9c43ffb3bd8">
               <id root="9b50dd9a-3500-4236-bbd9-2c1ff160d02f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The dosage of Donnatal® should be adjusted to the needs of the dividual patient to assure symptomatic control with a</paragraph>
                  <paragraph>minimum of adverse effects.</paragraph>
                  <paragraph>Donnatal® Tablets. Adults: One or two Donnatal® tablets three or four times a day according to condition and severity</paragraph>
                  <paragraph>of symptoms.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="L0f84b203-21fa-4a6f-b160-82f49019be77">
               <id root="b7c1e8d7-4901-4323-ba1b-0d15012c3f82"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot and dry skin,</paragraph>
                  <paragraph>dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation. Treatment should consist of gastric</paragraph>
                  <paragraph>lavage, emetics, and activated charcoal. If indicated, parenteral cholinergic agents such as physostigmine or</paragraph>
                  <paragraph>bethanechol chloride, should be used.</paragraph>
               </text>
               <effectiveTime value="20131122"/>
            </section>
         </component>
         <component>
            <section ID="L787b8916-ae3a-4b29-88a7-9380361950a0">
               <id root="5f4124bb-252b-488e-9750-6d324cf58391"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>How Supplied</title>
               <text>
                  <paragraph>NDC:68151-0607-1 in a PACKAGE of 1 TABLETS</paragraph>
               </text>
               <effectiveTime value="20140707"/>
            </section>
         </component>
         <component>
            <section ID="L7bdfccdb-b2e6-4f47-bf85-f627d1089d2b">
               <id root="2c7f5e51-6b11-4cd2-b919-c00209252061"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Belladonna Alkabids/Phenorbarb TAB</title>
               <text>
                  <renderMultiMedia referencedObject="lbl681510607"/>
               </text>
               <effectiveTime value="20131203"/>
               <component>
                  <observationMedia ID="lbl681510607">
                     <text>Label Image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="68151-0607.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>